Bethanechol

Introduction Overview

Generic Name

bethanechol

Brand Name

Urecholine

Dosage Form

Oral tablets

Drug Class

Miscellaneous genitourinary tract agents

Pharmacokinetics

Absorption:
Bethanechol is well absorbed orally, but it is important clinically to administer the drug on an empty stomach to reduce gastrointestinal side effects and optimize bioavailability. The onset of action generally occurs within 30 to 90 minutes after oral administration, with peak plasma concentrations typically attained within this window. Absorption can be affected by food intake, which may delay the onset and reduce bioavailability. Unlike some other parasympathomimetic agents, bethanechol is not significantly degraded by gastric acid, supporting its oral efficacy.

Distribution:
Bethanechol distributes primarily within extracellular fluids but does not extensively cross the blood-brain barrier due to its quaternary ammonium structure, which confers hydrophilicity and reduces CNS penetration. This characteristic limits central nervous system adverse effects. The volume of distribution approximates extracellular fluid volume, and plasma protein binding is minimal, facilitating free drug availability at cholinergic receptor sites. Distribution to genitourinary tissues is sufficient to elicit muscarinic receptor activation essential for therapeutic action.

Metabolism:
Bethanechol undergoes minimal hepatic metabolism. The drug is largely excreted unchanged, reflecting its resistant nature to enzymatic degradation, especially by cholinesterases. This metabolic stability prolongs its duration of action when compared to acetylcholine. However, it is hydrolyzed slowly, mainly by cholinesterase enzymes in peripheral tissues. Unlike acetylcholine, bethanechol is resistant to rapid inactivation, allowing for sustained therapeutic effects following a single dose.

Elimination:
Renal excretion is the primary route of elimination for bethanechol, with the unchanged drug being eliminated via glomerular filtration and tubular secretion. The elimination half-life is approximately 1 to 2 hours, which supports dosing schedules of several times daily depending on clinical indications. Renal impairment may reduce clearance, necessitating dose adjustments. The efficient renal excretion prevents accumulation in patients with normal renal function. Clinical pharmacokinetic studies emphasize monitoring in patients with compromised renal function to mitigate potential toxicity.

Dosage Forms

Available Dosage Forms:
- Oral tablets: 10 mg and 25 mg strengths.

Dosages for Adults and Adolescents:
- Initial dosing often starts at 10 to 25 mg orally three or four times per day, depending on the indication and patient tolerance.
- For urinary retention, a typical adult dose is 10 to 50 mg taken 3 to 4 times daily, administered on an empty stomach.
- Dose adjustments may be guided by clinical response and side effect profile.

Specific Patient Populations:
- The drug is not approved for use in individuals under 18 years of age.
- Caution is advised in elderly patients and those with renal insufficiency, with potential dose reduction to avoid excessive cholinergic effects.
- Not recommended during breastfeeding due to insufficient safety data.
- Pregnancy use should be considered only if clearly needed, with thorough risk-benefit assessment.

Clinical Guidelines:
- Administer on an empty stomach, at least 1 hour before or 2 hours after meals, to optimize absorption and limit gastrointestinal upset.
- Effects typically commence within 30 to 90 minutes, lasting about 1 hour.
- Proper storage in original containers with moisture-absorbing packets is recommended to maintain tablet integrity.

Mechanism Of Action

Bethanechol is a synthetic choline ester and a direct-acting muscarinic cholinergic agonist with selective affinity for muscarinic receptors located in the smooth muscle of the bladder and gastrointestinal tract. Unlike acetylcholine, bethanechol is resistant to hydrolysis by acetylcholinesterase, enabling prolonged muscarinic receptor stimulation. By mimicking the action of acetylcholine, bethanechol activates muscarinic receptors mainly of the M3 subtype, which are G-protein coupled receptors linked to phospholipase C activation.

In the urinary bladder, bethanechol-induced muscarinic receptor activation leads to increased intracellular inositol triphosphate (IP3) and diacylglycerol (DAG), leading to elevated intracellular calcium levels. This rise in calcium triggers contraction of detrusor muscle fibers, facilitating bladder emptying. The contraction of the detrusor muscle is especially critical in patients with urinary retention resulting from postoperative atony or neurogenic dysfunction.

Additionally, bethanechol stimulates muscarinic receptors in the gastrointestinal tract, increasing motility by enhancing smooth muscle tone and promoting peristalsis. This prokinetic effect is beneficial in selected disorders where gastrointestinal motility is impaired. Unlike nicotinic stimulation, bethanechol does not activate skeletal muscle receptors, thereby conferring some specificity.

Clinically, bethanechol’s muscarinic receptor agonism helps overcome functional urinary retention without significant effects on heart rate or blood pressure at therapeutic doses. Comparative studies have shown bethanechol’s distinct advantage over indirect cholinomimetics, such as neostigmine, by avoiding nicotinic receptor mediated side effects, thus providing a favorable safety and efficacy profile for genitourinary applications.

Pharmacological Actions

Direct muscarinic receptor agonist activity primarily at M3 receptors in the urinary bladder and gastrointestinal tract.
Stimulates detrusor muscle contraction, promoting urination in urinary retention conditions.
Enhances gastrointestinal smooth muscle tone and motility, improving peristalsis.
Resistant to acetylcholinesterase, leading to longer duration of action compared to acetylcholine.
Selective activation of muscarinic receptors avoiding nicotinic receptor stimulation.
Minimal central nervous system penetration due to quaternary ammonium structure.
Produces parasympathomimetic effects such as increased salivation, bronchial secretions, and sweating.
Does not significantly affect heart rate at therapeutic doses but may cause bradycardia in overdose.
Stimulates exocrine gland secretion, contributing to side effects like increased salivation and sweating.
Improves bladder muscle tone in atonic bladder post-surgery or childbirth.
Promotes gastric motility useful in some gastrointestinal motility disorders.
Minimal hepatic metabolism, predominantly eliminated unchanged via renal excretion.

Therapeutic Or Clinical Uses

Treatment of acute postoperative urinary retention and urinary retention associated with atony of the bladder.
Management of non-obstructive urinary retention, especially after childbirth or surgery.
Adjunct treatment in neurogenic bladder to promote micturition.
Occasionally used to stimulate gastrointestinal motility in selective cases of gastric atony or abdominal distension.
Facilitation of bladder emptying in patients with impaired detrusor muscle function.
Relief of urinary retention symptoms due to underactive bladder with functional impairment.
Evaluation of gastric reflux and esophageal function in specialized diagnostic procedures (off-label).
May be used diagnostically to assess cholinergic receptor responsiveness in genitourinary tract conditions.
Supportive treatment when catheterization is contraindicated or not preferred in urinary retention.
Not indicated for treatment of urinary retention caused by mechanical obstruction.
Therapeutic utility in selected patients with gastrointestinal hypomotility disorders refractory to other treatments.

Side Or Adverse Effects

Abdominal cramps and stomach discomfort due to increased gastrointestinal motility.
Nausea and diarrhea reflecting enhanced GI smooth muscle activity and secretions.
Increased salivation and excessive burping resulting from parasympathetic stimulation.
Headache and dizziness, possibly due to autonomic fluctuations.
Sweating, flushing, and a general feeling of warmth associated with muscarinic activation.
Urgent need to urinate or urinary frequency.
Watery eyes and transient vision changes including blurred vision due to muscarinic effect on ocular muscles.
Bradycardia or slow heart rate in overdose or sensitive individuals.
Potential for hypotension or light-headedness, especially on standing (orthostatic hypotension).
Wheezing or bronchoconstriction in susceptible patients, particularly those with asthma or reactive airway disease.
Rare hypersensitivity reactions including urticaria, angioedema, and anaphylaxis.
General malaise or weakness in some patients.
Excessive cholinergic stimulation may lead to salivation and gastrointestinal hyperactivity.
Risk of cholinergic crisis with overdose, manifesting as severe muscle cramps, excessive salivation, vomiting, and potentially respiratory distress.
Visual disturbances related to ciliary muscle spasm.

Precautions

Use with caution in patients with low blood pressure or bradycardia to prevent exacerbation of hemodynamic instability.
Avoid use in patients with asthma or other bronchospastic conditions due to risk of bronchoconstriction.
Monitor patients with cardiovascular disease, especially coronary artery disease, for arrhythmias and ischemic events.
Use cautiously in patients with hyperthyroidism or seizure disorders, as parasympathomimetic agents may exacerbate symptoms.
Avoid use in patients with active peptic ulcer disease or gastrointestinal obstruction due to increased motility and secretions.
Adjust dosing or avoid administration in patients with bladder outlet obstruction to prevent bladder rupture or worsening retention.
Do not use in patients with peritonitis or other inflammatory abdominal conditions.
Exercise caution in elderly patients who may be more susceptible to adverse autonomic effects including dizziness and falls.
Not recommended for use in pediatric patients under 18 years due to lack of safety and efficacy data.
Pregnant women should use only if clearly needed; consult healthcare provider for risk/benefit assessment.
Breastfeeding is contraindicated due to unknown excretion in human milk and potential for adverse effects in infants.
Inform patients about the potential for dizziness and advise care when operating machinery or driving.
Monitor renal function especially in elderly or patients with known renal impairment.
Patients should be advised to adhere strictly to the dosing regimen and avoid abrupt discontinuations.
Report any signs of allergic reactions or unusual side effects promptly to healthcare providers.

Warnings

Contraindicated in patients with known hypersensitivity to bethanechol or any component of the formulation.
Do not use in patients with urinary tract obstruction or mechanical obstruction of the gastrointestinal tract.
Avoid in patients with bradycardia or hypotension; bethanechol may exacerbate these conditions leading to syncope or cardiovascular compromise.
Use is contraindicated in patients with active asthma or other bronchospastic diseases due to risk of severe bronchoconstriction.
Should not be administered to individuals with active peptic ulcer disease due to risk of increased gastric acid secretion and ulcer exacerbation.
Contraindicated in patients with epilepsy or seizure disorders as parasympathomimetic stimulation may increase seizure frequency.
Avoid use in patients with recent bladder or intestinal surgery as stimulation of smooth muscle may disrupt healing.
Bethanechol can cause cholinergic crisis if overdosed, requiring immediate medical intervention.
Patients with Parkinson’s disease should avoid use due to potential worsening of symptoms related to cholinergic stimulation.
Use caution in patients with coronary artery disease as increased parasympathetic activity may provoke coronary insufficiency.
Immediate medical attention is warranted if signs of allergic reactions such as swelling of the face, difficulty breathing, or hives occur.
Do not exceed recommended doses; overdose can result in severe cholinergic toxicity manifesting with respiratory failure.

Contraindication

Known allergy or hypersensitivity to bethanechol or related compounds.
Urinary tract obstruction including bladder neck obstruction or urethral stricture.
Mechanical obstruction of the gastrointestinal tract (e.g., bowel obstruction).
Active asthma or other obstructive pulmonary diseases with bronchospasm.
Bradycardia or significant hypotension, especially if symptomatic or with syncope.
Coronary artery disease with unstable angina or recent myocardial infarction.
Peptic ulcer disease or active gastric and intestinal ulcers.
Epilepsy or seizure disorders.
Peritonitis or inflammation of the abdominal cavity.
Bladder or gastrointestinal surgery within recent postoperative period.
Parkinson’s disease due to potential exacerbation through increased cholinergic activity.
Pediatric patients under age 18 years due to lack of established safety and efficacy.
Pregnant or breastfeeding patients unless potential benefits outweigh risks and under medical supervision.

Drug Interactions

Concomitant use with other cholinergic agonists may potentiate muscarinic effects and increase risk of toxicity.
Interactions with anticholinergic agents may reduce the therapeutic efficacy of bethanechol.
Beta-blockers may enhance the bradycardic effects of bethanechol, increasing risk of hypotension and syncope.
Use with acetylcholinesterase inhibitors (e.g., neostigmine) may lead to additive cholinergic effects.
Antihistamines and tricyclic antidepressants may block muscarinic receptors reducing bethanechol efficacy.
Concurrent use with quinidine or procainamide might exacerbate cardiac conduction abnormalities.
Coadministration with ganglionic blockers may antagonize bethanechol’s parasympathomimetic actions.
Use with beta-2 agonists may paradoxically alter bronchial smooth muscle tone, requiring caution in respiratory disease.
Concomitant alcohol use may potentiate dizziness and hypotension side effects.
May affect the action of diabetes medications through stimulation of gastrointestinal motility impacting absorption.
Drugs that impair renal function may reduce bethanechol clearance, necessitating dose adjustment.
Anticholinergic agents used for overactive bladder (e.g., oxybutynin) may antagonize bethanechol.
Nonsteroidal anti-inflammatory drugs (NSAIDs) have no direct interaction but concurrent use should consider gastrointestinal tolerability.
Herbal supplements with cholinergic effects (e.g., ginkgo biloba) should be used cautiously to avoid excessive parasympathetic stimulation.
Drugs that cause hypotension may exacerbate bethanechol-induced blood pressure lowering effects.

Preparations Of The Drug

Bethanechol chloride oral tablets: commonly available in 10 mg and 25 mg strengths.
Tablets formulated for oral administration, requiring dosing on an empty stomach.
Packaged with moisture-absorbing packets to maintain tablet stability and potency.
Stored at room temperature away from excess moisture, heat, and light to preserve efficacy.
No injectable or intravenous commercial preparations marketed under the brand Urecholine.
Solutions and formulations for oral use are designed to target muscarinic receptors with minimal systemic adverse effects.
Prescriptions available by brand name Urecholine or generic bethanechol chloride tablets.
Compatible with standard oral delivery systems without special requirements.
No extended-release or combination formulations widely available for Urecholine at present.
Packaging includes patient information leaflets outlining administration and precautions.
Manufactured under good manufacturing practices to ensure batch consistency and safety.